| Sample Type | Treatment | Detection |
|---|---|---|
| HeLa cells | Camptothecin (1 µM, 1h) | Band at ~40 kDa |
| U2OS cells | Camptothecin (1 µM, 1h) | Band at ~40 kDa |
This antibody demonstrates high specificity for phosphorylated RPA2, with minimal cross-reactivity in untreated controls .
Western blotting (WB) and immunohistochemistry (IHC) are inferred based on similar antibody panels .
Phospho-RPA2 (T21) is a marker of replication stress, which correlates with clinical outcomes in ovarian cancer. A 2024 study (n = 244 patients) demonstrated that tumors with high pRPA2 foci (>16% cells with ≥2 foci) exhibited improved survival when treated with platinum chemotherapy or PARP inhibitors .
Platinum Chemotherapy: HR-proficient, pRPA2-High tumors achieved higher pathologic complete response rates (p < 0.01) compared to pRPA2-Low tumors .
PARP Inhibitors: pRPA2-High status predicted longer survival (HR = 0.53, p < 0.005) in recurrent tumors .
Phosphorylation of RPA2 at T21 and S33 sites facilitates replication fork adaptation under stress. Mutations at these sites (T21A/S33A) impair DNA synthesis during replication stress, leading to increased single-stranded DNA (ssDNA) and apoptosis .